Literature DB >> 19766408

Synchronous squamous cell carcinoma of the kidney, squamous cell carcinoma of the ureter, and sarcomatoid carcinoma of the urinary bladder: a case report.

Tadashi Terada1.   

Abstract

The author presents a unique case of a synchronous triple carcinoma of kidney, ureter, and urinary bladder. A 73-year-old man was admitted to our hospital because of hematuria and lumbago. Endoscopy and imaging modalities revealed a bladder tumor, a left ureter tumor, and a left kidney tumor. No other tumors were found in the body by imaging modalities. Cystectomy and left nephroureterectomy were performed. The bladder tumor was a large polypoid tumor consisting of pleomorphic sarcomatoid carcinoma (80%) and high-grade papillary urothelial carcinoma (20%), both invading the deep muscle layer. There were gradual merges between the two. The sarcomatous component was composed of malignant spindle, polygonal, and giant cells. Lymphovascular permeation was pronounced. Immunohistochemically, the sarcomatous element was positive for vimentin and various types of cytokeratins (CK), while the urothelial carcinoma element was positive for various types of CK and negative for vimentin. The ureter tumor was small and obstructed the ureter lumen. It was a pure squamous cell carcinoma without a urothelial component. The ureter tumor invaded the adventitia. A mild degree of lymphovascular invasion was recognized. Immunohistochemically, the tumor cells were positive for various types of CK but negative for vimentin. In the kidney, almost the entire kidney parenchyma was replaced by a tumor. The renal pelvis was broadly erosive but was free of apparent tumors. Histologically, the renal tumor was a pure squamous cell carcinoma without a urothelial component. Broad necrosis was present, and lymphovascular permeation was pronounced. The renal pelvis and calices were devoid of apparent tumor cells, but renal squamous cell carcinoma was present just beneath the pelvis and calices. Immunohistochemically, the kidney tumor was positive for various types of CK and negative for vimentin. 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19766408     DOI: 10.1016/j.prp.2009.07.021

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

1.  Solitary skin metastasis from sarcomatoid carcinoma of the bladder: a case report.

Authors:  Antonio Manzelli; Silvia Quaresima; Piero Rossi; Athanasios Petrou; Edoardo Ricciardi; Nicholas Brennan; Michael Kontos; Giuseppe Petrella
Journal:  J Med Case Rep       Date:  2011-09-28

2.  Primary kidney parenchyma squamous cell carcinoma mimicking xanthogranulomatous pyelonephritis: A case report.

Authors:  Zhao Wang; Bin Yan; Yong-Bao Wei; N A Hu; Qin Shen; Duo Li; Jin-Rui Yang; Xin Yang
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

3.  Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

4.  Cutaneous pseudolymphoma: a case report with an immunohistochemical study.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

Review 5.  Squamous cell carcinoma of the renal parenchyma presenting as hydronephrosis: a case report and review of the recent literature.

Authors:  Xirong Zhang; Yuanfeng Zhang; Chengguo Ge; Junyong Zhang; Peihe Liang
Journal:  BMC Urol       Date:  2020-07-20       Impact factor: 2.264

6.  Biological role and clinical value of miR-99a-5p in head and neck squamous cell carcinoma (HNSCC): A bioinformatics-based study.

Authors:  Yu-Ting Chen; Jian-Ni Yao; Yu-Tao Qin; Kai Hu; Fang Wu; Ye-Ying Fang
Journal:  FEBS Open Bio       Date:  2018-06-26       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.